Biological Phosphocalcic Metabolism and Coronary Artery Calcifications (BIOCAC)

French Cardiology Society

Status: Completed

Conditions: Cardiovascular Disease

Treatments: Other: 24 h urines analyses

Study type: Observational

Funder types: Other

Identifiers

NCT02792868

2015.02

Details and patient eligibility

About

Study a sample of patients in primary prevention, moderate cardiovascular risk (n = 83 patients), with normal, non-diabetic renal function. The investigators quantify the phophocalcic intake and excretion, realizing a food examination and a urine collection of 24 particular. The investigators will measure plasma levels of FGF23 serum calcium, phosphatemia, the investigators will calculate the tubular reabsorption of phosphate. The investigators will conduct a quantitative assessment of coronary calcification by a non-injected CT scan, measuring semi automated way Agatston calcium score. There will be an analysis of collinearity. An adjustment will be made for confounding variables in a generalized linear regression model.

Enrollment: 83 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hospitalization for a cardiovascular check in the Detection Centre and the Atherosclerosis Prevention (CHU Rangueil Toulouse)
• In primary prevention of coronary heart disease
• Introducing an intermediate cardiovascular risk according to the European SCORE equation, that is to say, a risk of cardiovascular death at 10 years greater than or equal to 1% and less than 5%
• signed the informed consent,

Exclusion criteria

• Chronic renal failure patients with an estimated GFR less than 60 mL / min / 1.73m2, due to alterations in phosphate metabolism,
• Patients receiving glucose-lowering therapy,
• Patients with a fasting blood glucose greater capillary or equal to 1.10 g / l, confirmed by a plasma glucose greater than or equal to 1.10g / l.
• The diuretic therapy patients (due to a change in urinary electrolytes)
• HIV-positive patients for HIV, antiretroviral (due to a change in urinary electrolytes)
• Pregnant women,
• Patients under judicial protection, guardianship or trusteeship.

Trial design

83 participants in 1 patient group

patient

Description:

patient with cardiovascular risk (moderate)

Treatment:

Other: 24 h urines analyses